Nascent Biotech, Inc. (OTCMKTS:NBIO – Get Free Report) crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.11 and traded as low as $0.08. Nascent Biotech shares last traded at $0.09, with a volume of 589,676 shares changing hands.
Nascent Biotech Stock Performance
The company has a 50-day moving average of $0.11 and a 200-day moving average of $0.14.
Nascent Biotech Company Profile
Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.
Recommended Stories
- Five stocks we like better than Nascent Biotech
- What is a Low P/E Ratio and What Does it Tell Investors?
- GitLab’s Weak Results Were Priced In; Time to Buy the Dip?
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Birkenstock Looks Like a Fit in Any Growth-Oriented Portfolio
- Best Stocks Under $10.00
- These Are the Most Active Congressional Trades This Quarter
Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
